Search company, investor...

SmartPill Corporation

smartpillcorp.com

Founded Year

1999

Stage

Acquired | Acquired

Total Raised

$12.62M

About SmartPill Corporation

The Smartpill Corporation is a medical device company that has developed the Smartpill Gi Monitoring System, Version 2. FDA released for the evaluation of suspected delayed gastric emptying and chronic constipation, the SmartPill GI Monitoring System is an exciting advancement in GI healthcare. SmartPill is a capsule-based, in-office procedure that calculates regional transit times providing a whole gut motility profile. In October 2012, The SmartPill Corporation was acquired by Given Imaging. The valuation of SmartPill Corporation was undisclosed. Other terms of the deal were not released.

Headquarters Location

3016 N.w. 82nd Ave.

Miami, Florida, 33122,

United States

716-882-0701

Missing: SmartPill Corporation's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: SmartPill Corporation's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

SmartPill Corporation Patents

SmartPill Corporation has filed 2 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/5/2007

11/16/2010

Neurotransmitters, Capacitors, Electronic circuits, TAAR1 agonists, Analog circuits

Grant

Application Date

9/5/2007

Grant Date

11/16/2010

Title

Related Topics

Neurotransmitters, Capacitors, Electronic circuits, TAAR1 agonists, Analog circuits

Status

Grant

Latest SmartPill Corporation News

Marizyme is Pleased to Announce the Appointment of David Barthel as CEO

Nov 16, 2021

November 16, 2021 14:55 ET JUPITER, Fla., Nov. 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme Inc. (“Marizyme” or the “Company”) (OTCQB:MRZM), is pleased to announce the hiring of Mr. David Barthel as the Chief Executive Officer for Marizyme. In his role Mr. Barthel will look to advance the Company’s technology pipeline and stay committed to the commercialization efforts of DuraGraft in Europe and Asia while focusing on the FDA submissions for DuraGraft and MATLOC 1 in the US. In addition, Mr. Barthel will lead the Company through its financing initiatives, strengthening the financial position of the Company in preparation for an anticipated Nasdaq listing in 2022. Mr. Barthel founded The SmartPill Corp. and led the company as CEO & President until its acquisition by medical device giant, Medtronic. Mr. Barthel successfully took The SmartPill company, developing an innovative ingestible sensor-based capsule for diagnosing GI motility disorders, from its initial patent, through the entire product development process, raising more than $70 million in multiple funding rounds. Mr. Barthel led his team through multiple clinical trials, manufacturing, FDA approval, commercialization and successful insurance reimbursement. After the acquisition by Medtronic, Mr. Barthel joined the company as Area Vice President, GIH Southeast Division. Most recently, Mr. Barthel was CEO of Health Logic Interactive Inc. (“Health Logic”) and its wholly owned Subsidiary, My Health Logic Inc. (“My Health Logic”), a company focused on developing an innovative point-of-care lab-on-chip digital diagnostic device technologies for chronic kidney disease. In less than a year, Mr. Barthel led the Company from an initial patent pending technology with proof-of-concept data to building an IP portfolio and further advancing our lab-on-chip technology platform. The Company also began development on its point-of-care device, MATLOC 1, which is expected to have a functional prototype ready for its clinical trials to take place in Q3 2022. Mr. Barthel was responsible for implementing product and software development partners, the preparation of an FDA pre-submission, leading discussions with several potential strategic partners, integrating a strong clinical and business team-based culture, and a diverse Scientific Advisory Board. He has also developed the business plan around the utilization of multiple partners for commercialization with the potential for multiple revenue streams that will ensure eventual success of the device. My Health Logic Inc., subsidiary of Health Logic which holds the MATLOC device technology and all accompanying agreements, is currently in the process of being acquired by Marizyme. Mr. Barthel earned a Bachelor of Arts Degree from St. Norbert College in De Pere, Wi and an MBA from Lake Forest Graduate School of Management in Lake Forest, II. Dr. Vithal Dhaduk, (Chairman) of the Board of Directors, stated the following: “We are very excited about acquiring My Health Logic and David Barthel becoming our CEO. My Health Logic developed the MATLOC technology, an innovative technology that has strong potential to improve the lives of millions of patients with chronic kidney disease. Bringing on the very dedicated and effective management group led by David Barthel will add strength to Marizyme's current team. This is a very strategic step for Marizyme to diversify and improve Marizyme's current product portfolio by adding more innovative, platform technologies and a strong management team. We are looking forward to bringing these new technologies to the market to serve a unique and unmet need in the chronic kidney and cardiac disease population. "   About Marizyme, Inc. Marizyme is an integrated life sciences company dedicated to the acquisition, development and commercialization of therapies that minimize mortality and costs in the acute care space. The Company's flagship product, DuraGraft®, is an intra-operative vascular graft storage solution that inhibits endothelial damage and leads to improved clinical outcomes by reducing the incidence of complications associated with vein graft failure in bypass surgery. DuraGraft enhances coronary artery bypass grafting (CABG) surgical outcomes by significantly reducing major adverse cardiac events such as repeat revascularization and myocardial infarction. DuraGraft is approved for use in the EU and several Asian countries but is not yet approved for use in the U.S. Marizyme is also focused on the development and marketing of products based on its clinically tested and previously patented protease based therapeutic Krillase® platform. Krillase is not approved for use in the U.S. For more information about Marizyme, visit  www.marizyme.com . Forward-Looking Statements This press release may contain certain forward-looking statements, including those relating to the Marizyme’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth  opportunities and other statements that are predictive in nature. The Company has made every reasonable effort to ensure the information and assumptions on which these statements are based are current, reasonable, and complete. However, a variety of factors, many of which are beyond the  Company’s control, affect the Company’s operations, performance, business strategy and results and  there can be no assurances that the Company’s actual results will not differ materially from those indicated herein. Additional written and oral forward-looking statements may be made by the Company from time to time. Forward-looking statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,”  “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and  unknown risks, including those risks set forth in the Company’s risk factor disclosure in the reports that Marizyme files with the Securities and Exchange Commission (SEC File No. 000-53223), uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Contact:

SmartPill Corporation Frequently Asked Questions (FAQ)

  • When was SmartPill Corporation founded?

    SmartPill Corporation was founded in 1999.

  • Where is SmartPill Corporation's headquarters?

    SmartPill Corporation's headquarters is located at 3016 N.w. 82nd Ave., Miami.

  • What is SmartPill Corporation's latest funding round?

    SmartPill Corporation's latest funding round is Acquired.

  • How much did SmartPill Corporation raise?

    SmartPill Corporation raised a total of $12.62M.

  • Who are the investors of SmartPill Corporation?

    Investors of SmartPill Corporation include Given Imaging, Rochester Angels, Primary Venture Partners, New York State Common Retirement Fund, American Capital and 7 more.

  • Who are SmartPill Corporation's competitors?

    Competitors of SmartPill Corporation include PulmonX, Prometheus Laboratories, Acelity, ReGear Life Sciences, BioBehavioral Diagnostics Company and 11 more.

Compare SmartPill Corporation to Competitors

V
Vitreo Retinal Technologies

Vitreo Retinal Technologies, Inc. is developing therapeutics for the treatment of serious ocular diseases.

N
NDO Surgical

Medical devices for the treatment of severe gastrointestinal disorders

b
btt

btt provides non-invasive and continuous wearable technology that tracks human brain temperature through the brain's thermal tunnel. The company was founded in 2006 and is based in Miami, Florida.

R
Rafael Medical Technologies

Rafael Medical has developed a novel anchoring system for safely implanting and retrieving a wide range of intra-vascular devices in a minimally invasive manner. Based on the technology, diagnostic and therapeutic devices can be delivered into small and large blood vessels alike by way of a small-sized delivery system. Following the completion of the SafeFlo Filter the company is now developing additional devices geared to the interventional cardiology market.

M
Mobius Therapeutics

Mobius Therapeutics is a commercial stage venture focused on ophthalmic surgery solutions. Its first product, Mitosol, is a system for delivering antifibrotic agents in glaucoma, refractive, and corneal surgery. The glaucoma indication is in active commercialization; the pterygium and refractive indications are awaiting approval by the Food and Drug Administration.

K
KT Tape

2nd place finisher at the 2009 BYU Business Plan Competition. KT Tape brings kinesiology therapeutic tape directly to the consumers. The tape has the same elasticity as skin and relieves pain by lifting skin off of the injured location to increase circulation. KT Tape already has an exclusive endorsement from Kerri Walsh -- U.S. Olympic volleyball player who wore the tape at the Beijing Olympics

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.